Trading around Chelsea Therapeutics CHTP got busy Thursday, with the shares down on the day. FDA는 첼시 테라퓨틱스의 약물 노르테라를 승인하기 전에 더 많은 데이터가 필요하다고 판단했습니다. The decision was almost as bad as an outright rejection for the mostly optimistic audience.